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underestimation of resource use costs. ConClusions: The study findings indicate 
that manufacturers should consider providing data supporting OS benefit versus 
relevant comparators. Also, a robust economic model including sensitivity analysis 
to adjust for uncertainties, and incorporating appropriate cost and utility values 
could be beneficial to gain access in CEA markets.
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objeCtives: Patient-reported outcomes (PROs) are designed to measure the unique 
patient perspective on an aspect(s) of a disease or the impact of treatment. After the 
development and validation of a PRO measure, often the next step is to understand 
how the PRO scores and changes are related to the clinical endpoints in order to 
better inform and interpret the newly developed PRO for clinician use or to provide 
greater insights into disease burden or treatment efficacy. Our objective is to review 
commonly used statistical Methods when assessing the association of PRO and 
clinical endpoints and to introduce alternate statistical applications. Methods: 
A review of the literature revealed several statistical Methods used to define and 
quantify the association between PROs and clinical endpoints including correlation 
analysis, responder/categorical analysis, linear and logistic regression and receiver-
operating curves. However, these methodologies typically examine the relationship 
at a single time-point, ignoring the longitudinal nature of the study design. Our 
research will use simulated longitudinal data to examine the association between 
PROs and clinical endpoints across multiple time-points and introduce alternate 
applications using mixed-models for repeated measures. We will provide a series of 
examples based on the simulated data to show how each method uniquely demon-
strates the relationship between these endpoints. ConClusion: To help stakehold-
ers understand the relevance of PROs, it is often an important step to assess the 
association of a PRO to existing clinical endpoints. Our research introduces alternate 
approaches to examine this association across multiple time-points which account 
for the longitudinal design found in most trials.
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bACkground: In many cases, medicines for ultra-rare disorders (URDs) have high 
acquisition costs and are associated with incremental cost per quality-adjusted 
life year (QALY) gained exceeding widely used benchmarks for cost effective-
ness. objeCtives: To address the underlying reasons why interventions for URDs 
often fail to meet conventional benchmarks for cost effectiveness and deliberate 
implications for formal Health Technology Assessments (HTAs) including economic 
evaluation. Methods: An international group of experts in health economics, med-
ical ethics, evidence-based medicine (EBM), and HTA met in conjunction with the 
Annual European ISPOR Congresses in November 2012, 2013, and 2014. results: 
In contrast to the principles of EBM, the logic of cost effectiveness (including bench-
marks for incremental cost per QALY gained, as applied by some HTA agencies as a 
measure of “value for money”) does not adequately capture well-established social 
norms and preferences regarding health care resource allocation. Such preferences 
include, but are not limited to, a priority for care for the worst off (related to initial 
health state), for those with more urgent conditions (the so called “rule of rescue”), 
and a relatively lower priority based upon capacity to benefit, as well as a dislike 
against “all or nothing” resource allocation decisions that might deprive certain 
groups of patients from any chance to access effective care. ConClusions: The 
group concluded that there exists a strong need for an improved or new paradigm to 
assess value for money. Candidates include direct social value measurement using 
the relative social willingness-to-pay or person trade-off instruments, combined 
with a greater role for budget impact analysis. As a pragmatic interim alternative, 
multi-criteria decision analysis may prove useful. Further systematic research into 
social preferences, including their valid measurement, should be prioritized relative 
to the continued application of a descriptively flawed framework based on bench-
marks for maximum incremental cost per QALY gained.
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objeCtives: To describe a framework for the integration of encompassing models of 
value into health technology assessment (HTA) decision processes, and to use this to 
work through the implications of implementing broader models of value, using an 
‘end-of-life premium’ as an exemplar proposition. Methods: Building on a scoping 
review of the literature on the role of values in HTA and the use of cost-effectiveness 
objeCtives: Patients with metastatic non-small cell lung cancer (NSCLC) whose 
tumors harbor exon 19 deletions or exon 21 (L858R) substitution mutations in the 
epidermal growth factor receptor (EGFR) gene are eligible for first line treatment 
with erlotinib or afatinib, tyrosine kinase inhibitors (TKIs) approved for use in the 
U.S. The relative clinical and economic impacts between these two agents remain 
unclear. Methods: A Markov model was developed in which patients could transi-
tion through three health states: Pre progression, progression, and death. Transition 
probabilities were derived from key clinical trials, peer-reviewed literature, and U.S. 
life tables. We assumed a progression free survival (PFS) hazard ratio (HR) of 1 in 
the base case, and a scenario analysis was performed using data from an indirect 
treatment comparison in which the PFS HR for erlotinib vs. afatinib was 0.44. Costs 
included those related to drug utilization, drug administration, and adverse events. 
We calculated the discounted (3%) incremental life expectancy, quality-adjusted 
life expectancy, and costs from a U.S. payer perspective. Probabilistic sensitivity 
analysis (PSA) was conducted to assess parameter uncertainty. results: Initiating 
treatment with erlotinib rather than afatinib resulted in comparable QALYs and 
modest decreased costs (-$895) in the base case. PSA indicated that at a threshold 
of $100,000/QALY, there was approximately a 60% probability that erlotinib is cost-
effective. In the scenario analysis (PFS HR: 0.44) we found that erlotinib treatment 
resulted in $35K greater costs and 0.274 additional QALYs gained, resulting in an 
ICER of $128K/QALY. ConClusions: Our analysis indicates that first-line treatment 
with erlotinib vs. afatinib may lead to similar quality adjusted life years gained but 
slightly lower costs. Depending on assumptions about the comparative effective-
ness, erlotinib may be in the range of being cost effective compared to afatinib, even 
with significantly longer PFS and treatment duration.
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objeCtives: To analyze all available clinical trial evidence to determine whether 
dose-intensive therapy Results in longer overall survival (OS) or progression-free 
survival (PFS) in DHL patients who have poorer prognoses than standard-risk diffuse 
large B-cell lymphoma patients. Methods: Eleven observational studies evaluat-
ing first-line treatments in 401 adult DHL patients were included (no randomized 
trials were available). Individual patient data (IPD) were obtained from authors of 2 
studies; IPD was extracted from digitized Kaplan-Meier survival curves of 3 studies. 
Median survival (n= 4) and percent survival at month 24 (n= 2) were available from 
the remaining publications. All data types were synthesized within a random-effects 
Weibull proportional hazards model using a Bayesian analysis framework to esti-
mate OS and PFS of each treatment. IPD points were given Weibull distributions, cen-
sored as necessary. The number of survivors at median or month 24 was estimated 
from the total number of patients and assumed binomially distributed. The binomial 
probabilities were then used to inform the Weibull survival parameters. Treatments 
of interest were R-CHOP (standard dose), R-EPOCH (intermediate dose), and R-Hyper-
CVAD or R CODOX-M/R-IVAC (dose-intense [DI]). results: Appropriateness of the 
Weibull and proportional hazards assumptions was verified by graphical tests using 
the available IPD. Estimated hazard ratios (HRs) of OS (n= 374) relative to R-CHOP 
were 0.77 (95% credible interval: 0.51-1.13) for R-EPOCH and 0.89 (0.62-1.27) for DI, 
indicating no significant differences for either higher-dose treatment. R-EPOCH, 
but not DI, was associated with a marginally significant increase in PFS (n= 357) 
with HRs of 0.66 (0.44-0.96) and 0.74 (0.51-1.05), respectively. ConClusions: This 
novel methodology combines several data types, allowing synthesis of data from 
a larger number of studies than could have been possible with standard analysis 
techniques. The totality of the available published data suggested R-EPOCH chemo-
therapy extended PFS, but not OS in DHL patients.
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objeCtives: To compare the reimbursement recommendations and ration-
ale for decisions for metastatic breast cancer therapies across seven HTA agen-
cies. Methods: We assessed HTA reports published by AHRQ, HAS, IQWiG, NICE, 
PBAC, pCODR and SMC for metastatic breast cancer therapies. Decisions were cat-
egorized as positive, negative or deferred, and recommendation summaries were 
analyzed to identify clinical and economic factors affecting decisions. results: 
Thirty-nine HTA reports were identified, of which 46% had a positive recommenda-
tion. No relevant HTA reports were published by AHRQ. Highest positive decisions 
were provided by pCODR (80%), all being conditional on improving cost-effectiveness 
to an acceptable level. Major factors driving positive decisions were overall survival 
(OS) benefit for IQWiG and pCODR; acceptable efficacy and safety for HAS; and 
cost-effectiveness versus relevant comparator(s) for NICE, PBAC and SMC. Highest 
percentage of negative decisions was provided by NICE (75%). HAS cited lack of 
survival benefit (OS or progression-free survival) or quality-of-life improvement, 
or unacceptable safety profile for negative decisions; whereas, pCODR and IQWiG 
mainly considered lack of OS benefit and inappropriate comparators. Negative 
decisions by NICE, PBAC and SMC were mainly due to economic modelling issues 
that resulted in high ICERs. NICE also considered lack of quality-of-life benefit and 
unacceptable safety profile for negative decisions. Major economic modelling issues 
across HTA agencies included inappropriate extrapolation of immature OS data, 
carry-over of benefit into post-treatment states, improper cross-over adjustment, 
non-inclusion of adverse event-related disutilities and costs, underestimation of 
post-progression utility and costs, overestimation of comparator drug costs, and 
